S&P Capital IQ Initiates Coverage on Medifocus, Inc. in Standard & Poor's Factual Stock Reports

S&P Capital IQ Initiates Coverage on Medifocus, Inc. in Standard & Poor's Factual Stock Reports

NEW YORK--(BUSINESS WIRE)-- S&P Capital IQ announced today that it has commenced Standard & Poor's Factual Stock Report coverage on Medifocus, Inc.

Medifocus, Inc. (TSXV: MFS, OTC: MDFZF.PK) develops and commercializes minimally invasive, focused-heat treatment devices and systems. The Company has developed two advanced therapeutic products: Prolieve, for the treatment of BPH (Benign Prostatic Hyperplasia), acquired from Boston Scientific in July 2012, and the APA-1000, microwave technology, for treatment of Breast Cancer. Prolieve is a FDA approved commercial product and is generating revenue. The APA-1000 is in advanced stage of clinical development and has received approval to enter the final pivotal phase-III clinical trial, the final step before commercial approval. Medifocus has a device treatment pipeline of additional therapies based on its existing comprehensive portfolio of patented technologies.

The Prolieve System is a medical device that both heats the prostate and dilates the prostatic urethra. The Prolieve System is the only minimally invasive treatment option for the symptoms of enlarged prostate (BPH) in men indicated by the FDA as an in office treatment alternative to drug therapy. Medifocus is well positioned to address the $8 billion market for BHP treatments thru traditional sales channels and its unique mobile treatment service. The acquisition of Prolieve transforms Medifocus from a development stage medical device company to a mature medical treatment and device company with a revenue-generating commercial product.

Medifocus' APA 1000 breast cancer treatment system is a focused-heat treatment that can improve the efficacy of neo-adjuvant chemotherapy in shrinking large breast cancer tumors, improving the chance of breast conservation, and decreasing the need for radical breast surgery. Focused microwaves can be used to shrink breast tumors up to eight cm in diameter improving the chance of breast conservation for these patients. The first indication for treatment of medium sized breast tumors has a total addressable marketplace of $4 billion.

The company's goal is to improve outcomes and standards of care by deploying minimally invasive treatments and devices. Using the Prolieve technology platform and the APA focused-heat platform, the Company is well positioned to develop a rich pipeline of minimally invasive and side effect-free focused-heat treatment systems and devices for cancer and other diseases.

Standard & Poor's Factual Stock Report coverage on Medifocus Inc will also be accessible on an ongoing basis to the investment community by scores of buy-side institutions and sell-side firms that utilize S&P Capital IQ research and information platforms daily. Millions of self-directed investors also have access to the report via their e-brokerage accounts. Please visit www.medifocusinc.com for additional information.

About Standard & Poor's Factual Stock Reports

Currently profiling approximately 500 issuers, Standard & Poor's Factual Stock Reports, produced by S&P Capital IQ, increase market awareness of issuers in the investment community with insightful commentary and key statistics and information. Standard & Poor's Factual Stock Reports provide factual research coverage about company fundamentals and business prospects, thereby enabling information about covered companies to reach a wide investor audience of Buy and Sell-side investors. Updated weekly with the latest pricing, trading volume, and other data, the reports include recent developments, a financial review, key operating information, industry and peer comparisons, institutional holdings analysis, Street Consensus and opinions, performance charts, business summary, fundamental data, and news. Because coverage of these reports is underwritten by the issuer, S&P Capital IQ does not offer investment opinions concerning the advisability of investing in these stocks.

Standard & Poor's Factual Stock Reports are produced separately from any other analytic activity of S&P Capital IQ or related organizations. S&P Capital IQ does not trade on its own account.

About S&P Capital IQ

S&P Capital IQ, a business line of The McGraw-Hill Companies (NYS: MHP) , is a leading provider of multi-asset class and real time data, research and analytics to institutional investors, investment and commercial banks, investment advisors and wealth managers, corporations and universities around the world. We provide a broad suite of capabilities designed to help track performance, generate alpha, and identify new trading and investment ideas, and perform risk analysis and mitigation strategies. Through leading desktop solutions such as the S&P Capital IQ, Global Credit Portal and MarketScope Advisor desktops; enterprise solutions such as S&P Capital IQ Valuations, and Compustat; and research offerings, including Leveraged Commentary & Data, Global Markets Intelligence, and company and funds research, S&P Capital IQ sharpens financial intelligence into the wisdom today's investors need. For more information visit www.spcapitaliq.com.

Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50418142〈=en

Medifocus, Inc.
John Mon, 410-290-5734
S&P Capital IQ
Richard Albanese, 212-438-3647
Media Relations
Michael Privitera, 212-438-6679

KEYWORDS:   United States  North America  New York


The article S&P Capital IQ Initiates Coverage on Medifocus, Inc. in Standard & Poor's Factual Stock Reports originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story